Development and Evaluation of Ursolic acid Loaded Dendrimers

Ursolic acid (UA), a reversible cholinesterase inhibitor, shows promise in Alzheimer's disease (AD) treatment. This study aimed to develop a nanoparticulate drug delivery system using PAMAM G0 dendrimers for UA, targeting sustained release and enhanced brain targeting, and subjected to NMR and in silico analysis. This study utilized UA-loaded PAMAM dendrimers for in silico molecular docking studies to evaluate their potential against dementia. Using AutoDock software, the formulation was evaluated against dementia targets, including β-amyloid fibril (PDB ID: 2ENS) and AGER ligands. The results showed that UA-loaded PAMAM dendrimers had a higher binding affinity (score: -8.5) compared to known UA inhibitors. This suggests that UA-loaded PAMAM dendrimers could effectively target key aspects of dementia, indicating potential for more effective dementia therapies. Further experimental validation is necessary to confirm these findings.